TY - JOUR T1 - A multi-centric, cross-sectional study on COVID-19 in Bangladesh: Clinical epidemiology and short-term outcomes in recovered individuals JF - medRxiv DO - 10.1101/2020.09.09.20191114 SP - 2020.09.09.20191114 AU - Adnan Mannan AU - H. M. Hamidullah Mehedi AU - Naim Uddin Hasan A Chy AU - Md. Omar Qayum AU - Farhana Akter AU - Abdur Rob AU - Prasun Biswas AU - Sanjida Hossain AU - Mustak Ibn Ayub Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/10/12/2020.09.09.20191114.abstract N2 - Background COVID-19 turned into a global pandemic rapidly. This study was aimed to investigate SARS-CoV-2 associated epidemiology and clinical outcomes in Bangladesh in order to understand the future course of COVID-19 pandemic and develop prevention approaches.Design and Methods A cross-sectional retrospective study was conducted for a sample of 1,021 RT-PCR confirmed COVID-19 cases admitted in six different hospitals in Bangladesh and who recovered four weeks prior to the interview date.Results Of the total sample, 111 (10.9%) cases were asymptomatic while the number of symptomatic cases were 910 (89.1%). Higher prevalence of COVID-19 persisted in the male population (75%), cohorts having B (+) ve blood group (36.3%) and for the 31-40 age group. More than 85% of the sample reported a BCG vaccination mark. Common symptoms observed in our study samples were fever (72.4%), cough (55.9%), loss of taste (40.7%) and body ache (40%); whereas among the biochemical parameters, Neutrophil (46.4%), D-dimer (46.1%), and Ferritin (37.9%) levels were found elevated. Post-COVID complications including pain (31.8%), loss of concentration (24.4%) and anxiety or depression (23.1%) were also found significantly prevalent in the symptomatic cases with commodities.Conclusion Our study has shown that adult males aged in between 31-40 in Bangladesh are more vulnerable to being infected with COVID-19. The study also indicates a rising trend of the asymptomatic cases as the pandemic progresses deeper in time, and hence, deployment of interventions to curb further spread of community infection is necessary to avoid the grave outcomes of COVID-19 in Bangladesh.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The protocol was approved by IRB of 250 bedded General Hospital Chittagong. The ethical approval number is 2020-03-027.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe authors agree. ER -